Vitality Biopharma Receives DEA Approval for Cannabinoid Pharma Development Facility

Approval of cannaboside pharmaceutical research included review by FDA and California Research Advisory Panel LOS ANGELES, CA–(Dec 21, 2016) – Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and...

Vitality Biopharma to Present at the 9th Annual LD Micro Main Event

LOS ANGELES, CA / December 5, 2016 / Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, announced today that it will be presenting at the 9th Annual LD...

Vitality Biopharma Advances Cannabosides for Treatment of Narcotic Bowel Syndrome

Opiate-induced severe abdominal pain leads to escalating dosages and drug dependence LOS ANGELES, CA–(Nov 16, 2016) – Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that...

Vitality Biopharma Announces International Patent Filing for Cannabinoid Pharmaceuticals

Once concluded, IP protection extends to 2035 or longer in USA and all major markets worldwide  LOS ANGELES, CA – (November 9, 2016) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious...

Vitality Biopharma Reports on Initial Cannabinoid Drug Formulation Studies

Water solubility significantly improved more than 100-fold, enabling novel pharmaceutical applications LOS ANGELES, CA–(Oct 19, 2016) – Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today...

Vitality Biopharma Develops Cannabinoid Alternatives to Opiate Prescription Pain Medications

Cannabosides Enable Targeted Pain Relief and Avoid Psychoactivity of THC Through Site-Specific Delivery LOS ANGELES, CA–Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, wishes to advise that a...

Vitality Biopharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference

LOS ANGELES, CA–Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders announced today that Company CEO, Robert Brooke will be presenting at the Rodman & Renshaw 18th Annual Global...

What We Should Know About Opiates and Prescription Drug Abuse

Here at Vitality Biopharma, we are at the forefront of creating new cannabinoid pharmaceuticals, which are known to provide substantial pain relief. We believe these drugs will ultimately prove to be very potent and far safer than the options in widespread use today. In part, we aim to deliver this through site-specific delivery, which enables...

Vitality Biopharma Announces Expansion of Prodrug Pharmaceutical Portfolio

Company Protects Intellectual Property Addressing Solution That Over 50 Pharma Companies Have Invested More Than $1B to Research LOS ANGELES, CA–Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders,...